Pfizer signs cancer immunotherapy deal with France's Cellectis
June 18, 2014 at 02:43 AM EDT
June 18 (Reuters) - U.S. drugmaker Pfizer, which failed last month in a $118 billion bid to buy AstraZeneca , said on Wednesday it had signed a deal with French biotech Cellectis to develop immunotherapy drugs in cancer.